{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:57:01Z","timestamp":1790578621064,"version":"4.1.0"},"reference-count":62,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["AIDS Care"],"DOI":"10.1080\/09540121.2026.2733373","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:30:31Z","timestamp":1790577031000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and factors associated with discontinuation of dolutegravir in individuals starting antiretroviral therapy in Brazil: a retrospective cohort study"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7855-7295","authenticated-orcid":false,"given":"Mariana","family":"Jacob Veloso","sequence":"first","affiliation":[{"name":"Department of Social Pharmacy, School of Pharmacy, Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-5195","authenticated-orcid":false,"given":"Luana","family":"Andrade Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Department of Social Pharmacy, School of Pharmacy, Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-7202","authenticated-orcid":false,"given":"Matheus Marchesotti Dutra","family":"Ferraz","sequence":"additional","affiliation":[{"name":"Department of Computer Science, Institute of Exact Sciences","place":["Belo Horizonte, Brazil"]},{"name":"Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-0659","authenticated-orcid":false,"given":"Maria Das Gra\u00e7as","family":"Braga","sequence":"additional","affiliation":[{"name":"Department of Social Pharmacy, School of Pharmacy, Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255912"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04252-4"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000002210"},{"issue":"3","key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0000000000001351","article-title":"Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir","volume":"31","author":"Bonfanti P.","year":"2017","unstructured":"Bonfanti, P. , Madeddu, G. , Gulminetti, R. , Squillace, N. , Orofino, G. , Vitiello, P. , Rusconi, S. , Celesia, B. M. , Maggi, P. , & Ricci, E. (2017). Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS, 31(3), 455\u2013460. https:\/\/pubmed.ncbi.nlm.nih.gov\/28079544\/","journal-title":"AIDS"},{"issue":"5","key":"e_1_3_3_6_1","first-page":"1388","article-title":"Understanding information related to antiretroviral treatment among individuals infected with HIV","volume":"20","author":"Braga Ceccato M. das G.","year":"2004","unstructured":"Braga Ceccato, M. das G. , Ac\u00farcio, F. de A. , Bonolo, P. de F. , Rocha, G. M. , & Guimar\u00e3es, M. D. C. (2004). Understanding information related to antiretroviral treatment among individuals infected with HIV. Cadernos de Sa\u00fade P\u00fablica, 20(5), 1388\u20131397. https:\/\/www.scielosp.org\/pdf\/csp\/v20n5\/34.pdf","journal-title":"Cadernos de Sa\u00fade P\u00fablica"},{"issue":"1","key":"e_1_3_3_7_1","first-page":"22","article-title":"Evaluaci\u00f3n de factores asociados a la comprensi\u00f3n del tratamiento en pacientes que inician la terapia antirretroviral","volume":"27","author":"Braga Ceccato M. das G.","year":"2009","unstructured":"Braga Ceccato, M. das G. , Ac\u00farcio, F. de A. , Vallano, A. , Comini C\u00e9sar, C. , & Guimar\u00e3es, M. D. C. (2009). Evaluaci\u00f3n de factores asociados a la comprensi\u00f3n del tratamiento en pacientes que inician la terapia antirretroviral. Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, 27(1), 22\u201327. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0213005X08000037","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"e_1_3_3_8_1","unstructured":"BRAZIL . (2018). Clinical protocol and therapeutic guidelines for the management of HIV infection in adults. Accessed: June 2.Accessed: June 2 2024. https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/pcdts\/2013\/hiv-aids\/pcdt_manejo_adulto_12_2018_web.pdf\/view"},{"key":"e_1_3_3_9_1","unstructured":"BRAZIL . (2024a). Clinical protocol and therapeutic guidelines for the management of HIV infection in adults: Module 1: Treatment. Accessed: June 2 2024. https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/pcdts"},{"key":"e_1_3_3_10_1","unstructured":"BRAZIL . (2024b). Epidemiological bulletin HIV and AIDS 2024. Accessed: Mar. 16 2025. https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/boletins-epidemiologicos\/2024\/boletim_hiv_aids_2024e.pdf\/view"},{"key":"e_1_3_3_11_1","unstructured":"BRAZILIAN INSTITUTE OF GEOGRAPHY AND STATISTICS (IBGE) . (2024). Panel: Color or race. IBGE. S. l.Accessed: June 8 2025. https:\/\/www.ibge.gov.br\/painel-cor-ou-raca\/"},{"key":"e_1_3_3_12_1","unstructured":"BRAZIL. Ministry of Health. Department of Health Surveillance. Department of STIs AIDS and Viral Hepatitis . (2017). Clinical protocol and therapeutic guidelines for the management of HIV infection in adults. Ministry of Health. Bras\u00edlia DF.Accessed: June 15 2025. http:\/\/www.aids.gov.br\/pcdt"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61221-0"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14010163"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0078"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1590\/1980-549720250015"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12121202"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky497"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad026"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001279"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174426"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001590"},{"key":"e_1_3_3_24_1","unstructured":"EUROPEAN AIDS CLINICAL SOCIETY (EACS) . (2018). Guidelines: Version 9.0 October 2017 \u2013 updated July 2018. EACS. Brussels.Accessed: April 30 2025. https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/"},{"key":"e_1_3_3_25_1","unstructured":"EUROPEAN AIDS CLINICAL SOCIETY (EACS) . (2025). Guidelines version 13.0. EACS. Bruxelas. October.Accessed: May 22 2026. https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002374"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2022.2029814"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15040924"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1742058X15000120"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0107-7"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002250"},{"key":"e_1_3_3_32_1","unstructured":"Gregg F. & Eder D. (2015). Dedupe. S. l.Accessed: July 19 2024. https:\/\/docs.dedupe.io\/_\/downloads\/en\/latest\/pdf\/"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2018.10.024"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12710"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.4314\/jcmphc.v34i3.5"},{"issue":"1","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12939-016-0427-4","article-title":"Social inequalities in the prevalence of self-reported chronic non-communicable diseases in Brazil: National health survey 2013","volume":"15","author":"Malta D. C.","year":"2016","unstructured":"Malta, D. C. , Bernal, R. T. I. , de Souza, M. de F. M. , Szwarcwald, C. L. , Lima, M. G. , & Barros, M. B. de A. (2016). Social inequalities in the prevalence of self-reported chronic non-communicable diseases in Brazil: National health survey 2013. International Journal for Equity in Health, 15(1), 153. https:\/\/pubmed.ncbi.nlm.nih.gov\/27852264\/","journal-title":"International Journal for Equity in Health"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1590\/1980-549720210011.supl.2"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1590\/1413-81232015203.16182014"},{"key":"e_1_3_3_40_1","volume-title":"Social determinants of health: Non-communicable chronic diseases and their risk and protective factors in the Brazilian adult population","author":"Malta D. C.","year":"2025","unstructured":"Malta, D. C. , Silva, A. G. da , Gomes, C. S. , & Souza, J. B. (2025). Social determinants of health: Non-communicable chronic diseases and their risk and protective factors in the Brazilian adult population (1st ed.). Rema Editora; ACT Health Promotion; Federal University of Minas Gerais. https:\/\/actbr.org.br\/wp-content\/uploads\/2025\/05\/DETERMINANTES-SOCIAIS-ebook-final.pdf.","edition":"1"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(15)00027-2"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25227"},{"issue":"8","key":"e_1_3_3_43_1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0000000000002533","article-title":"Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients","volume":"34","author":"Nasreddine R.","year":"2020","unstructured":"Nasreddine, R. , Florence, E. , Vandercam, B. , Moutschen, M. , Goffard, J.-C. , De Munter, P. , Delforge, M. , Marinus, W. , & De Wit, S. (2020). Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients. AIDS, 34(8), 1151\u20131159. https:\/\/journals.lww.com\/aidsonline\/abstract\/2020\/07010\/effectiveness_of_dolutegravir_based_antiretroviral.6.aspx","journal-title":"AIDS"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0178"},{"issue":"2","key":"e_1_3_3_45_1","first-page":"1","article-title":"Eq\u00fcidade e reforma em sistemas de servi\u00e7os de sa\u00fade: o caso do SUS","volume":"15","author":"Paim J. S.","year":"2006","unstructured":"Paim, J. S. (2006). Eq\u00fcidade e reforma em sistemas de servi\u00e7os de sa\u00fade: o caso do SUS. Sa\u00fade E Sociedade, 15(2), 1\u201313. https:\/\/www.scielo.br\/j\/sausoc\/a\/4j9Z4NpGd6C9zKVXZFC7zdp\/?lang=pt","journal-title":"Sa\u00fade E Sociedade"},{"issue":"6","key":"e_1_3_3_46_1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting","volume":"72","author":"Pe\u00f1afiel J.","year":"2017","unstructured":"Pe\u00f1afiel, J. , de Lazzari, E. , Padilla, M. , Rojas, J. , Gonzalez-Cordon, A. , Blanco, J. L. , Blanch, J. , Marcos, M. A. , Lonca, M. , Martinez-Rebollar, M. , Laguno, M. , Tricas, A. , Rodriguez, A. , Mallolas, J. , Gatell, J. M. , & Martinez, E. (2017). Tolerability of integrase inhibitors in a real-life setting. Journal of Antimicrobial Chemotherapy, 72(6), 1752\u20131759. https:\/\/academic.oup.com\/jac\/article\/72\/6\/1752\/5862641","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2023.2203914"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/hiv.s452130"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(13)70257-3"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jana.2007.10.006"},{"issue":"2","key":"e_1_3_3_51_1","first-page":"1","article-title":"Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting","volume":"28","author":"Rolle C.-P.","year":"2023","unstructured":"Rolle, C.-P. , Castano, J. , Nguyen, V. , Patel, K. , Hinestrosa, F. , & DeJesus, E. (2023). Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting. Antiviral Therapy, 28(2), 1\u20135. https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/13596535231163703","journal-title":"Antiviral Therapy"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.6018\/EGLOBAL.437711"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1590\/0102-311x00106914"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1397291"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0b013e3283612419"},{"key":"e_1_3_3_56_1","unstructured":"UNITED STATES. Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Accessed: April 30 2025. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"e_1_3_3_57_1","unstructured":"UNITED STATES. Department Of Health And Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults And Adolescents 2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed: Mar. 16 2025. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-155"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-008-9490-1"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215541"},{"key":"e_1_3_3_61_1","unstructured":"WORLD HEALTH ORGANIZATION (WHO) . (2018). Statement on potential safety signal in infants born to women taking dolutegravir. May 18.Accessed: April 27 2025. https:\/\/www.who.int\/medicines\/publications\/drugalerts\/Statement_on_DTG_18May_2018final.pdf?ua=1"},{"key":"e_1_3_3_62_1","unstructured":"WORLD HEALTH ORGANIZATION (WHO) . (2019). WHO recommends dolutegravir as preferred HIV treatment option in all populations. World Health Organization. Mexico City. 22 Jul.Accessed: May 7 2025. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations"},{"key":"e_1_3_3_63_1","unstructured":"WORLD HEALTH ORGANIZATION (WHO) . (2021). Consolidated guidelines on HIV prevention testing treatment service delivery and monitoring: Recommendations for a public health approach. World Health Organization. Geneva.Accessed: May 10 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240031593"}],"container-title":["AIDS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09540121.2026.2733373","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/09540121.2026.2733373","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09540121.2026.2733373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:30:37Z","timestamp":1790577037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09540121.2026.2733373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":62,"alternative-id":["10.1080\/09540121.2026.2733373"],"URL":"https:\/\/doi.org\/10.1080\/09540121.2026.2733373","relation":{},"ISSN":["0954-0121","1360-0451"],"issn-type":[{"value":"0954-0121","type":"print"},{"value":"1360-0451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=caic20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=caic20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}